Moore Capital Management’s Cytokinetics CYTK Stock Holding History

Moore Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.13M	Hold	25,000	–	–	0.03%	381
2026 Q1	$1.65M	Hold	25,000	–	–	0.03%	312
2025 Q4	$1.59M	Hold	25,000	–	–	0.02%	405
2025 Q3	$1.37M	Sell	25,000 -10,000	-29%	-$412K	0.02%	391
2025 Q2	$1.16M	Hold	35,000	–	–	0.01%	364
2025 Q1	$1.41M	Hold	35,000	–	–	0.03%	293
2024 Q4	$1.65M	Hold	35,000	–	–	0.02%	339
2024 Q3	$1.85M	Hold	35,000	–	–	0.03%	309
2024 Q2	$1.9M	Hold	35,000	–	–	0.03%	273
2024 Q1	$2.45M	Buy	35,000 +30,000	+600%	+$2.32M	0.04%	251
2023 Q4	$417K	Sell	5,000 -20,000	-80%	-$724K	0.01%	306
2023 Q3	$737K	Hold	25,000	–	–	0.01%	316
2023 Q2	$816K	Hold	25,000	–	–	0.01%	319
2023 Q1	$880K	Hold	25,000	–	–	0.02%	302
2022 Q4	$1.15M	Hold	25,000	–	–	0.03%	317
2022 Q3	$1.21M	Sell	25,000 -25,000	-50%	-$1.2M	0.03%	400
2022 Q2	$1.97M	Sell	50,000 -25,000	-33%	-$1.01M	0.05%	335
2022 Q1	$2.76M	Sell	75,000 -25,000	-25%	-$888K	0.07%	314
2021 Q4	$4.56M	Buy	+100,000	New	+$3.86M	0.09%	243
2020 Q4	–	Sell	-50,000	Closed	-$1.08M	–	538
2020 Q3	$1.08M	Buy	+50,000	New	+$1.17M	0.02%	292
2017 Q3	–	Sell	-50,000	Closed	-$605K	–	230
2017 Q2	$605K	Buy	+50,000	New	+$695K	0.02%	172

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Moore Capital Management's CYTK Position: Q2 2026 in Review

Moore Capital Management held its Cytokinetics (CYTK) position steady in Q2 2026 at 25,000 shares worth $2.13M. The position accounts for 0.03% of the portfolio, ranked #381.

Moore Capital Management first reported a position in CYTK in Q2 2017 and has held it in 21 quarters since. The position peaked at $4.56M in Q4 2021. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Moore Capital Management held 25,000 shares of Cytokinetics worth $2.13M as of Q2 2026.
Moore Capital Management left its Cytokinetics share count unchanged in Q2 2026.
Cytokinetics made up 0.03% of Moore Capital Management's portfolio in Q2 2026, its #381 holding.
Moore Capital Management first reported a position in Cytokinetics in Q2 2017 and has held it in 21 quarters since.
Moore Capital Management's Cytokinetics position peaked at $4.56M in Q4 2021.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Moore Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.